Ligand Pharmaceuticals Incorporated (LGND) — Capital Reinvestment Ratio
Ligand Pharmaceuticals Incorporated (LGND) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($48.69 Million) in capital expenditures ($228.00K). See Ligand Pharmaceuticals Incorporated (LGND) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Ligand Pharmaceuticals Incorporated Capital Reinvestment Ratio (2003–2025)
This chart tracks Ligand Pharmaceuticals Incorporated's Capital Reinvestment Ratio across 16 annual periods.
Annual Capital Reinvestment Ratio for Ligand Pharmaceuticals Incorporated (2003–2025)
Year-by-year Capital Reinvestment Ratio for Ligand Pharmaceuticals Incorporated from 2003 to 2025. For live market cap and broader valuation context, see market cap of Ligand Pharmaceuticals Incorporated.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $49.36 Million | $452.00K | ▼ -95.5% |
| 2024 | 0.20x | $97.05 Million | $19.64 Million | ▼ -81.4% |
| 2023 | 1.09x | $49.58 Million | $53.85 Million | ▲ +735.4% |
| 2022 | 0.13x | $137.85 Million | $17.92 Million | ▲ +16.9% |
| 2021 | 0.11x | $78.80 Million | $8.76 Million | ▲ +36.1% |
| 2020 | 0.08x | $54.59 Million | $4.46 Million | ▲ +33.3% |
| 2018 | 0.06x | $194.06 Million | $11.89 Million | ▼ -19.9% |
| 2017 | 0.08x | $93.57 Million | $7.15 Million | ▼ -83.0% |
| 2016 | 0.45x | $63.00 Million | $28.32 Million | ▲ +72.7% |
| 2015 | 0.26x | $41.73 Million | $10.86 Million | ▲ +19.0% |
| 2014 | 0.22x | $20.57 Million | $4.50 Million | ▼ -8.3% |
| 2013 | 0.24x | $20.69 Million | $4.94 Million | ▼ -99.6% |
| 2012 | 53.69x | $161.00K | $8.64 Million | ▲ +1161.7% |
| 2005 | 4.26x | $8.37 Million | $35.60 Million | ▲ +579.4% |
| 2004 | 0.63x | $5.75 Million | $3.60 Million | ▼ -93.8% |
| 2003 | 10.16x | $274.00K | $2.78 Million | — |